2. 本产品为化学成分确定培养基（Chemically Defined Medium，CDM），不含任何动物源性成分（Animal-Derived Component- Free，ADCF)。
3. 本产品含有氨基酸，维生素，葡萄糖、脂类、无机盐和微量元素，不含生长因子、水解物、多肽和酚红。
4. 干粉培养基含有 P188，不含 HT 和 L-谷氨酰胺。
公司简介
上海迈邦生物科技有限公司（简称“迈邦生物”或“MediumBank”）成立于2019年，是一家专注于提供上游生物工艺综合解决方案的高科技生物技术企业。迈邦生物拥有多种细胞系的目录化培养基产品，并提供细胞培养基优化开发、细胞培养工艺开发、干粉/液体培养基代工生产及分析检测等定制化服务。 迈邦生物自创立以来，凭借着丰富的创新研发和技术服务能力，产品与服务已涵盖CHO细胞、HEK293细胞、昆虫细胞、T细胞/干细胞、Sp2/0/NS0细胞、Vero细胞等各大细胞平台，多数产品的性能及优化开发服务达到国际领先水平。2021年，迈邦生物GMP标准建设的MFG1一期产能正式投产，MFG2二期量产化基地建设持续推进中；2022年，零缺陷通过ISO13485质量体系认证，完成生产管理及质量体系的再升级；2023年，荣获“专精特新”称号，完成多家国内上市生物药企的质量审计，率先完成双补料培养基（MaxFA/FB）DMF备案,多款产品成功出海。 目前，迈邦生物的客户涵盖单抗、融合蛋白、动物或人用疫苗、IVD、细胞基因治疗和细胞培养肉等多种类生物医药企业。迈邦的产品及服务已在国内外超过600+生物医药企业得到验证，产品被广泛应用于生物医药研发、临床申报及商品化生产等不同阶段，并获得行业内数百家生物医药企业的认可、信赖和支持。 迈邦（MediumBank），让生物工艺更简单、更高效! Shanghai Mediumbank Biotechnology Co., LTD. (MediumBank) was established in 2019. It is a high-tech biotechnology enterprise focused on providing integrated solutions for upstream bioprocess. MediumBank has cataloged media products for a variety of cell lines and provides customized services such as media optimization and development (MOD), cell culture processing development, original entrusted manufacture for dry powder and liquid media, cell culture supernatant analysis and detection. Since its establishment, with professional experience and technical accumulation, MediumBank's products and services have covered CHO cells, HEK293 cells, insect cells, T cells/stem cells, Sp2/0 & NS0 cells, Vero cells and other major cell platforms, the performance of most products and services have reached the international leading level. In 2021, MediumBank's MFG1 production capacity, constructed to GMP standards, officially commenced production, the construction of the MFG2 mass production base continued to make progress. In 2022, the company flawlessly passed the ISO13485 quality system certification, achieving further upgrades in production management and quality systems. In 2023, MediumBank was awarded the title of " specialized, high-end and innovation-driven" completed quality audits by several Chinese listed biopharmaceutical companies, was the first to complete the DMF filing for the dual feed medium (MaxFA/FB), and successfully expanded several products to international markets. Currently, MediumBank’s clients encompass a wide range of biopharmaceutical companies, including those focused on monoclonal antibodies, fusion proteins, vaccines for animals or humans, IVD, cell and gene therapies, and cultured meat. MediumBank's products and services have been validated by over 600+ biopharmaceutical companies worldwide, widely used in various stages of biopharmaceutical research and development, clinical filings, and commercial production, earning recognition, trust, and support from hundreds of companies in the industry.. Currently, MediumBank Biotech's clients encompass a wide range of biopharmaceutical companies, including those focused on monoclonal antibodies, fusion proteins, vaccines for animals or humans, IVD, cell and gene therapies, and cultured meat. MediumBank's products and services have been validated by over 600+ biopharmaceutical companies worldwide, widely used in various stages of biopharmaceutical research and development, clinical filings, and commercial production, earning recognition, trust, and support from hundreds of companies in the industry. MediumBank makes bioprocessing much simpler and more efficient!
